Tumor-Induced Osteomalacia - Global Strategic Business Report

The global market for Tumor-Induced Osteomalacia was estimated at US$114.5 Million in 2024 and is projected to reach US$129.5 Million by 2030, growing at a CAGR of 2.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Tumor-Induced Osteomalacia market.

Global Tumor-Induced Osteomalacia Market - Key Trends & Drivers Summarized

Why Is Tumor-Induced Osteomalacia a Unique Challenge in Endocrinology and Oncology?

Tumor-Induced Osteomalacia (TIO) is a rare disorder where tumors secrete excess FGF23, causing phosphate loss, weak bones, and chronic pain. Diagnosis is often delayed due to vague symptoms and the difficulty of locating small, slow-growing tumors responsible for the condition.

Once identified, surgical removal of the tumor usually resolves symptoms. However, inoperable or hidden tumors require long-term management with phosphate and vitamin D supplements, which are often insufficient for full recovery.

How Are Diagnostic Innovations and Targeted Therapies Changing TIO Management?

Imaging advances using somatostatin receptor-targeted tracers are improving tumor localization. Blood tests measuring FGF23 have become essential for diagnosing and tracking disease progression.

Burosumab, a monoclonal antibody that blocks FGF23, is a game-changing therapy for non-resectable cases. It restores phosphate levels, reduces pain, and improves mobility, offering targeted treatment where surgery is not an option.

The Growth in the Tumor-Induced Osteomalacia Market Is Driven by Several Factors

Market growth is driven by improved diagnostics, awareness, and the emergence of biologics like burosumab. Rare disease research funding and policy incentives are increasing. Collaborative efforts among hospitals, research institutions, and pharmaceutical companies are bringing more attention and innovation to this neglected segment.

Scope Of Study:

The report analyzes the Tumor-Induced Osteomalacia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Treatment (Drugs & Supplements Treatment, Surgery Treatment); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Drugs & Supplements Treatment segment, which is expected to reach US$87.9 Million by 2030 with a CAGR of a 2.5%. The Surgery Treatment segment is also set to grow at 1.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $31.2 Million in 2024, and China, forecasted to grow at an impressive 4.0% CAGR to reach $24.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Tumor-Induced Osteomalacia Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Tumor-Induced Osteomalacia Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Tumor-Induced Osteomalacia Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Amgen Inc., Amolyt Pharma, Ascendis Pharma A/S, Bayer AG, BridgeBio Pharma and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Tumor-Induced Osteomalacia market report include:

• Amgen Inc.
• Amolyt Pharma
• Ascendis Pharma A/S
• Bayer AG
• BridgeBio Pharma
• Chugai Pharmaceutical Co., Ltd.
• CRISPR Therapeutics
• Debiopharm Group
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Ionis Pharmaceuticals, Inc.
• Kyowa Kirin Co., Ltd.
• Merck & Co., Inc.
• Novo Nordisk A/S
• OPKO Health, Inc.
• Pfizer Inc.
• Radius Health, Inc.
• Regeneron Pharmaceuticals, Inc.
• Ultragenyx Pharmaceutical Inc.
• Visterra, Inc. (Otsuka subsidiary)

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.